Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients
- PMID: 26753955
- DOI: 10.1007/s13277-015-4776-1
Comparison of efficacy and safety of three different chemotherapy regimens delivered with concomitant radiotherapy in inoperable stage III non-small cell lung cancer patients
Abstract
Concomitant administration of chemotherapy and radiotherapy is currently recognized as the standard of treatment in locally advanced inoperable non-small cell lung cancer (NSCLC). Our study aimed to compare the efficacy and toxicities of three different chemotherapy regimens delivered concurrently with radiotherapy. We retrospectively reviewed the clinical records of patients who received the PE (cisplatin, 50 mg/m(2), on days 1, 8, 29, and 36 plus etoposide, 50 mg/m(2), on days 1 to 5 and 29 to 33), PD (docetaxel, 20 mg/m(2), on day 1 plus cisplatin, 20 mg/m(2), on day 1, every week), and PC (carboplatin, AUC 2 plus paclitaxel, 45 mg/m(2), on day 1, every week) regimens concurrently with radiotherapy. A total of 227 patients were evaluated in the study. Median follow-up time was 13 months (2-101). There were 27 females (11.9 %) and 200 males (88.1 %) with a median age of 61 (38-82) years. The PD group had higher rates of esophagitis, mucositis, and anemia (p < 0.05). The PC group had higher rates of neuropathy (p = 0.000). The progression-free survival (PFS) time was 10 months for patients in the PC group, 15 months for patients in the PD group, and 21 months for the PE group (p = 0.010). Patients in the PC group had a median overall survival time of 23 months, those in the PD group 27 months, and those in the PE group 36 months (p = 0.098). Combination of cisplatin-etoposide with radiotherapy led to a more favorable outcome compared with the other two regimens. It shows generally manageable toxicity profile and compliance to treatment is noticeable.
Keywords: Concurrent chemoradiation; Non-small cell lung cancer; Stage III.
Similar articles
-
Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.Strahlenther Onkol. 2003 Dec;179(12):823-31. doi: 10.1007/s00066-003-1127-8. Strahlenther Onkol. 2003. PMID: 14652671
-
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer.Cancer Med. 2013 Dec;2(6):916-24. doi: 10.1002/cam4.142. Epub 2013 Oct 16. Cancer Med. 2013. PMID: 24403265 Free PMC article.
-
Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer.J Clin Oncol. 1996 May;14(5):1642-8. doi: 10.1200/JCO.1996.14.5.1642. J Clin Oncol. 1996. PMID: 8622083 Clinical Trial.
-
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085. Ann Thorac Surg. 2004. PMID: 15464470 Review.
-
Docetaxel in combined-modality treatment of inoperable locally or regionally advanced lung cancer.Lung Cancer. 2004 Dec;46 Suppl 2:S13-21. doi: 10.1016/s0169-5002(04)80037-0. Lung Cancer. 2004. PMID: 15698527 Review.
Cited by
-
Therapeutic management options for stage III non-small cell lung cancer.World J Clin Oncol. 2017 Feb 10;8(1):1-20. doi: 10.5306/wjco.v8.i1.1. World J Clin Oncol. 2017. PMID: 28246582 Free PMC article. Review.
-
Comparison of post-chemoradiotherapy pneumonitis between Asian and non-Asian patients with locally advanced non-small cell lung cancer: a systematic review and meta-analysis.EClinicalMedicine. 2023 Sep 25;64:102246. doi: 10.1016/j.eclinm.2023.102246. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781162 Free PMC article.
-
Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III Non-Small-Cell Lung Cancer: Results of KINDLE-Vietnam Cohort.Front Oncol. 2022 May 23;12:842296. doi: 10.3389/fonc.2022.842296. eCollection 2022. Front Oncol. 2022. PMID: 35677172 Free PMC article.
-
Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.Thorac Cancer. 2020 Apr;11(4):898-906. doi: 10.1111/1759-7714.13333. Epub 2020 Feb 18. Thorac Cancer. 2020. PMID: 32068962 Free PMC article. Clinical Trial.
-
Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort.Ther Adv Med Oncol. 2023 Nov 22;15:17588359231212182. doi: 10.1177/17588359231212182. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38028146 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical